How GLP-1 drugs like liraglutide curb appetite and boost insulin
Molecular mechanisms mediating metabolic benefits of glucagon-like peptide-1 receptor agonists
Looks at how GLP-1 medicines like liraglutide change cells in the brain and pancreas to help people with obesity and type 2 diabetes eat less and release more insulin.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-11231247 on NIH RePORTER |
What this research studies
This project examines how GLP-1 receptor agonists act in the hypothalamus and pancreatic beta cells to reduce food intake and increase insulin secretion. Researchers will focus on molecular pathways such as mTORC1 signaling, a PKA-driven modification of the mTORC1 regulator Raptor, and the role of the HIF transcription factor in promoting glycolysis. Work will use laboratory experiments on cells and tissue models and mechanistic experiments that build on prior findings with liraglutide. The goal is to map the chain of molecular events that link GLP-1 receptor activation to metabolic benefits.
Who could benefit from this research
Good fit: People with obesity or type 2 diabetes who are taking or considering GLP-1 medications like liraglutide would be the most relevant group.
Not a fit: People without metabolic disorders or whose conditions do not involve appetite or insulin regulation are unlikely to benefit directly from this work.
Why it matters
Potential benefit: Could point to ways to make GLP-1 treatments more effective or reduce side effects for people with obesity or type 2 diabetes.
How similar studies have performed: GLP-1 drugs are already proven to improve blood sugar control and reduce weight, but the specific molecular mechanisms targeted here are newer and less tested.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Ayala, Julio E — Vanderbilt University
- Study coordinator: Ayala, Julio E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.